Cargando…
A dual‐strain Lactobacilli reuteri probiotic improves the treatment of residual pockets: A randomized controlled clinical trial
AIM: To examine the adjunctive effect of a Lactobacillus reuteri probiotic (ATCC PTA 5289 & DSM 17938) on the re‐instrumentation of residual pockets. MATERIALS AND METHODS: This randomized, double‐blind, placebo‐controlled study included 39 previously non‐surgically treated periodontitis patient...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6973056/ https://www.ncbi.nlm.nih.gov/pubmed/31520543 http://dx.doi.org/10.1111/jcpe.13198 |
_version_ | 1783489965819166720 |
---|---|
author | Laleman, Isabelle Pauwels, Martine Quirynen, Marc Teughels, Wim |
author_facet | Laleman, Isabelle Pauwels, Martine Quirynen, Marc Teughels, Wim |
author_sort | Laleman, Isabelle |
collection | PubMed |
description | AIM: To examine the adjunctive effect of a Lactobacillus reuteri probiotic (ATCC PTA 5289 & DSM 17938) on the re‐instrumentation of residual pockets. MATERIALS AND METHODS: This randomized, double‐blind, placebo‐controlled study included 39 previously non‐surgically treated periodontitis patients. A re‐instrumentation was carried out, and probiotic and/or placebo drops were applied according to the study protocoll. Patients afterwards received lozenges to use 2×/day for 12 weeks. Probing pocket depth (PPD), recession, bleeding on probing and plaque levels were analysed, next to the microbiological impact. RESULTS: No effects of the probiotic drops could be found. However, after 24 weeks, the overall PPD in the probiotic lozenges group (2.64 ± 0.33 mm) was significantly lower compared to the control lozenges (2.92 ± 0.42 mm). This difference was even more pronounced in moderate (4–6 mm) and deep (≥7 mm) pockets. In the probiotic lozenges group, there were also significantly more pockets converting from ≥4 mm at baseline to ≤3 mm at 24 weeks (67 ± 18% versus 54 ± 17%) and less sites in need for surgery (4 ± 4% versus 8 ± 6%). However, the probiotic products did not influence the microbiological counts of the periodontopathogens. CONCLUSION: The adjunctive consumption of L. reuteri lozenges after re‐instrumentation improved the PPD reduction, without an impact on pocket colonization with periodontopathogens. |
format | Online Article Text |
id | pubmed-6973056 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-69730562020-01-27 A dual‐strain Lactobacilli reuteri probiotic improves the treatment of residual pockets: A randomized controlled clinical trial Laleman, Isabelle Pauwels, Martine Quirynen, Marc Teughels, Wim J Clin Periodontol Periodontal Therapy AIM: To examine the adjunctive effect of a Lactobacillus reuteri probiotic (ATCC PTA 5289 & DSM 17938) on the re‐instrumentation of residual pockets. MATERIALS AND METHODS: This randomized, double‐blind, placebo‐controlled study included 39 previously non‐surgically treated periodontitis patients. A re‐instrumentation was carried out, and probiotic and/or placebo drops were applied according to the study protocoll. Patients afterwards received lozenges to use 2×/day for 12 weeks. Probing pocket depth (PPD), recession, bleeding on probing and plaque levels were analysed, next to the microbiological impact. RESULTS: No effects of the probiotic drops could be found. However, after 24 weeks, the overall PPD in the probiotic lozenges group (2.64 ± 0.33 mm) was significantly lower compared to the control lozenges (2.92 ± 0.42 mm). This difference was even more pronounced in moderate (4–6 mm) and deep (≥7 mm) pockets. In the probiotic lozenges group, there were also significantly more pockets converting from ≥4 mm at baseline to ≤3 mm at 24 weeks (67 ± 18% versus 54 ± 17%) and less sites in need for surgery (4 ± 4% versus 8 ± 6%). However, the probiotic products did not influence the microbiological counts of the periodontopathogens. CONCLUSION: The adjunctive consumption of L. reuteri lozenges after re‐instrumentation improved the PPD reduction, without an impact on pocket colonization with periodontopathogens. John Wiley and Sons Inc. 2019-11-14 2020-01 /pmc/articles/PMC6973056/ /pubmed/31520543 http://dx.doi.org/10.1111/jcpe.13198 Text en © 2019 The Authors. Journal of Clinical Periodontology published by John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Periodontal Therapy Laleman, Isabelle Pauwels, Martine Quirynen, Marc Teughels, Wim A dual‐strain Lactobacilli reuteri probiotic improves the treatment of residual pockets: A randomized controlled clinical trial |
title | A dual‐strain Lactobacilli reuteri probiotic improves the treatment of residual pockets: A randomized controlled clinical trial |
title_full | A dual‐strain Lactobacilli reuteri probiotic improves the treatment of residual pockets: A randomized controlled clinical trial |
title_fullStr | A dual‐strain Lactobacilli reuteri probiotic improves the treatment of residual pockets: A randomized controlled clinical trial |
title_full_unstemmed | A dual‐strain Lactobacilli reuteri probiotic improves the treatment of residual pockets: A randomized controlled clinical trial |
title_short | A dual‐strain Lactobacilli reuteri probiotic improves the treatment of residual pockets: A randomized controlled clinical trial |
title_sort | dual‐strain lactobacilli reuteri probiotic improves the treatment of residual pockets: a randomized controlled clinical trial |
topic | Periodontal Therapy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6973056/ https://www.ncbi.nlm.nih.gov/pubmed/31520543 http://dx.doi.org/10.1111/jcpe.13198 |
work_keys_str_mv | AT lalemanisabelle adualstrainlactobacillireuteriprobioticimprovesthetreatmentofresidualpocketsarandomizedcontrolledclinicaltrial AT pauwelsmartine adualstrainlactobacillireuteriprobioticimprovesthetreatmentofresidualpocketsarandomizedcontrolledclinicaltrial AT quirynenmarc adualstrainlactobacillireuteriprobioticimprovesthetreatmentofresidualpocketsarandomizedcontrolledclinicaltrial AT teughelswim adualstrainlactobacillireuteriprobioticimprovesthetreatmentofresidualpocketsarandomizedcontrolledclinicaltrial AT lalemanisabelle dualstrainlactobacillireuteriprobioticimprovesthetreatmentofresidualpocketsarandomizedcontrolledclinicaltrial AT pauwelsmartine dualstrainlactobacillireuteriprobioticimprovesthetreatmentofresidualpocketsarandomizedcontrolledclinicaltrial AT quirynenmarc dualstrainlactobacillireuteriprobioticimprovesthetreatmentofresidualpocketsarandomizedcontrolledclinicaltrial AT teughelswim dualstrainlactobacillireuteriprobioticimprovesthetreatmentofresidualpocketsarandomizedcontrolledclinicaltrial |